BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jan 9, 2018
Finance

Stars in China

...cell transplantation (HSCT) Merck & Co. Inc. (NYSE:MRK) / Pfizer Inc. (NYSE:PFE) FDA approves Steglatro ertugliflozin...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Jan 3, 2018
Clinical News

FDA approves Steglatro from Merck and Pfizer for Type II diabetes

...FDA approved Steglatro ertugliflozin from Merck & Co. Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) as an...
...The agency also approved the drug in two fixed-dose combinations -- Steglujan ertugliflozin/sitagliptin and Segluromet ertugliflozin/metformin...
...Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Steglatro ertugliflozin Business: Endocrine/Metabolic Jennie Walters ertugliflozin ertugliflozin/metformin ertugliflozin/sitagliptin sitagliptin Merck...
BioCentury | Dec 22, 2017
Company News

FDA approves Steglatro for Type II diabetes

...FDA approved Steglatro ertugliflozin from Merck & Co. Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) as an...
...The agency also approved the drug in two fixed-dose combinations -- Steglujan ertugliflozin/sitagliptin and Segluromet ertugliflozin/metformin...
...launch is planned for February at a WAC of $8.94 per day. The partners co-developed ertugliflozin...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin/sitagliptin regulatory update

...Pfizer said FDA and EMA accepted NDAs and MAAs for review for ertugliflozin, ertugliflozin/sitagliptin and ertugliflozin/metformin...
...metformin and ertugliflozin with Merck’s diabetes drug Januvia sitagliptin (see BioCentury, May 6, 2013 ). Ertugliflozin...
...Product: Ertugliflozin /sitagliptin Business: Endocrine/Metabolic Julian Zhu Merck & Co. Inc. Pfizer Inc. Dipeptidyl peptidase-4 (DPP-4) (CD26) Sodium-glucose cotransporter 2 (SGLT2) ertugliflozin/sitagliptin...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin/metformin regulatory update

...Pfizer said FDA and EMA accepted NDAs and MAAs for review for ertugliflozin, ertugliflozin/sitagliptin and ertugliflozin/metformin...
...metformin and ertugliflozin with Merck’s diabetes drug Januvia sitagliptin (see BioCentury, May 6, 2013 ). Ertugliflozin...
...New York, N.Y. Product: Ertugliflozin /metformin Business: Endocrine/Metabolic Julian Zhu Merck & Co. Inc. Pfizer Inc. Sodium-glucose cotransporter 2 (SGLT2) ertugliflozin/metformin...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin regulatory update

...Pfizer said FDA and EMA accepted NDAs and MAAs for review for ertugliflozin, ertugliflozin/sitagliptin and ertugliflozin/metformin...
...metformin and ertugliflozin with Merck’s diabetes drug Januvia sitagliptin (see BioCentury, May 6, 2013 ). Ertugliflozin...
...Inc. (NYSE:PFE), New York, N.Y. Product: Ertugliflozin ( MK-8835 , PF-4971729 , PF-04971729) Business: Endocrine/Metabolic Julian Zhu ertugliflozin MK-8835 PF-04971729 PF-4971729 Merck...
BioCentury | Oct 3, 2016
Finance

ASH and others

...otitis externa Ph III data 4Q16 Pfizer Inc. (NYSE:PFE) / Merck & Co. Inc. (NYSE:MRK) Ertugliflozin...
BioCentury | Sep 26, 2016
Clinical News

Ertugliflozin: Phase III data

...NDAs to FDA for ertugliflozin and for fixed-dose combination tablets of ertugliflozin plus Januvia and ertugliflozin...
...to co-develop and co-commercialize worldwide Pfizer’s ertugliflozin and fixed-dose combinations of ertugliflozin with metformin and ertugliflozin...
...Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Ertugliflozin ( MK-8835 , PF-4971729 , PF-04971729...
Items per page:
1 - 10 of 25